European Institute of Oncology / Istituto Europeo di Oncologia (IEO)


Research / Science organisation

Location:
Milano / Mailand, Italy


Publications in cooperation with FAU scientists


Go to first page Go to previous page 1 of 2 Go to next page Go to last page
Mayer, I.A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M.,... Arteaga, C.L. (2019). A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB). Clinical Cancer Research, 25(10), 2975-2987. https://dx.doi.org/10.1158/1078-0432.CCR-18-3160
Denkert, C., Budczies, J., Regan, M.M., Loibl, S., Dell’Orto, P., von Minckwitz, G.,... Viale, G. (2019). Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment. https://dx.doi.org/10.1007/s10549-018-05112-9
Govers, T.M., Hessels, D., Vlaeminck-Guillem, V., Schmitz-Draeger, B.J., Stief, C.G., Martinez-Ballesteros, C.,... Schalken, J.A. (2019). Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases, 22(1), 101-109. https://dx.doi.org/10.1038/s41391-018-0076-3
Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403. https://dx.doi.org/10.1530/ERC-18-0332
Capdevila, J., Bodei, L., Davies, P., Gorbounova, V., Jensen, R.T., Knigge, U.P.,... Wiedenmann, B. (2019). Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms. Neuroendocrinology, 108(1), 18-25. https://dx.doi.org/10.1159/000493319
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Yao, J.C., Yao, J.C., Fazio, N., Li, D., Pavel, M.E., Strosberg, J.,... Singh, S. (2018). ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment. (pp. 218-218).
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Valle, J., Herbst, F.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Fasching, P., Fernandez Abad, M., Garcia-Saenz, J.A., Schneeweiss, A., Guarneri, V., Colleoni, M.,... Slamon, D. (2017). Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer. (pp. 225-+).
Guarneri, V., Fasching, P., Fernandez Abad, M., Garcia-Saenz, A., Schneeweiss, A., Colleoni, M.,... Slamon, D. (2017). Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer. (pp. 19-19).
Guo, Q., Burgess, S., Turman, C., Bolla, M.K., Wang, Q., Lush, M.,... Pharoah, P.D.P. (2017). Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 46(6), 1814-1822. https://dx.doi.org/10.1093/ije/dyx131
Pavel, M.E., Singh, S., Strosberg, J.R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M.P.,... Yao, J.C. (2017). Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 18(10), 1411-1422. https://dx.doi.org/10.1016/S1470-2045(17)30471-0
Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F.,... Pommier, R. (2017). Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Oncotargets and Therapy, 10, 5013-5030. https://dx.doi.org/10.2147/OTT.S142087
Jiao, X., Aravidis, C., Marikkannu, R., Rantala, J., Picelli, S., Adamovic, T.,... Lindblom, A. (2017). PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 8(61), 102769-102782. https://dx.doi.org/10.18632/oncotarget.21800
Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P.,... Goss, P. (2017). Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Research and Treatment, 162(3), 479-488. https://dx.doi.org/10.1007/s10549-017-4130-y
Hamdi, Y., Soucy, P., Adoue, V., Michailidou, K., Canisius, S., Lemacon, A.,... Simard, J. (2016). Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 7(49), 80140-80163. https://dx.doi.org/10.18632/oncotarget.12818
Ghoussaini, M., French, J.D., Michailidou, K., Nord, S., Beesley, J., Canisus, S.,... Edwards, S.L. (2016). Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 99(4), 903-911. https://dx.doi.org/10.1016/j.ajhg.2016.07.017
Horne, H.N., Chung, C.C., Zhang, H., Yu, K., Prokunina-Olsson, L., Michailidou, K.,... Figueroa, J.D. (2016). Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 11(8). https://dx.doi.org/10.1371/journal.pone.0160316
Guo, Y., Andersen, S.W., Shu, X.-O., Michailidou, K., Bolla, M.K., Wang, Q.,... Zheng, W. (2016). Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. Plos Medicine, 13(8). https://dx.doi.org/10.1371/journal.pmed.1002105
Liu, J., Loncar, I., Collee, J.M., Bolla, M.K., Dennis, J., Michailidou, K.,... Hollestelle, A. (2016). rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 6. https://dx.doi.org/10.1038/srep36874

Last updated on 2016-22-06 at 08:39